This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Veterinary TfR1 Therapeutic Antibody Development
Background of TfR1
The expression of TfR1 significantly increases in certain pathological conditions, such as in tumor cells. In tumor types with high TfR1 expression, it becomes a potential target for companion animal cancer therapy. BioVenic has established a platform for the development of veterinary TfR1 therapeutic antibodies, providing a comprehensive one-stop service that covers the entire antibody development process, aiding in exploring the therapeutic potential of veterinary TfR1 antibodies.
Background of TfR1
| Full Name | Transferrin receptor 1 |
|---|---|
| Aliases | CD71, IMD46, p90, T9, TFR, TFR1, TFRC, TR, TRFR. |
| Target Profile | TfR1 belongs to the TFR family, and is a transmembrane glycoprotein composed of a large extracellular domain, a transmembrane region, and a smaller intracellular tail. It mediates iron uptake by binding with transferrin (Tf) in the serum. The iron-loaded Tf forms a complex that is recognized and internalized into cells via TfR1. |
MoA of TfR1
The widespread overexpression of TfR1 in cancer cells is linked to its complex regulatory mechanisms and interconnections. This increased expression is primarily to meet the high demand for iron by rapidly proliferating tumor cells. TfR1 enhances iron uptake by binding with mutated HFE protein. Additionally, intracellular iron concentrations regulate TFRC transcription by modulating the binding of iron regulatory proteins (IRP1 and IRP2) to TFRC mRNA. This concentration also influences the activity of key proteins such as c-Jun, cyclin D, and C-myc. Various miRNAs also play a role in regulating TFRC transcription. These biological processes collectively drive cell cycle progression and tumor cell growth, positioning TfR1 as a potential target for cancer therapy.
Fig.1 Schematic diagram of TfR1 and its regulatory effects on tumors in cancer cells.1
Application in Veterinary Therapeutics
Studies on TfR1 expression in companion animal tumors have involved canine brain tumors, canine malignant oral and nasal tumors, canine osteosarcoma, canine lymphoma, and feline mammary tumors. In these types of tumors, an increase in TfR1 expression has been observed, indicating that iron metabolism and TfR1 could be potential new targets for treating these companion animal tumor diseases. The use of veterinary TfR1 therapeutic antibodies has the potential to negatively affect the TfR1-mediated iron uptake in tumor cells, thereby impacting the growth of tumors in companion animals.
Veterinary TfR1 Therapeutic Antibody Development Services
TfR1 is increasingly expressed in many cancers of companion animals, making it a potent target for cancer therapy. BioVenic provides veterinary TfR1 therapeutic antibody development services. Our services span the entire process, from antigen preparation and animal immunization to antibody production and characterization, ensuring the development of high-quality, highly specific veterinary therapeutic antibodies. Our team employs emerging technologies and methods, including hybridoma technology, single B cell technology, and phage display technology, to ensure that the developed antibodies precisely target TfR1. Additionally, we offer customized species-specific antibody development services to meet the unique needs of different types of companion animals.
Please click the link below for more information about our veterinary TfR1 therapeutic antibody development services.
Why Choose Us?
BioVenic offers comprehensive support in veterinary TfR1 therapeutic antibody development, utilizing a variety of advanced methods to ensure the efficient selection of antibodies with high specificity and affinity.
We provide personalized solutions for different companion animals such as canine and feline, reducing the immunogenicity of antibodies and enhancing the safety and efficacy of treatment.
Our professionals rigorously control the quality at every stage of antibody development, from design to production, ensuring that each step meets the high standards required for clinical application.
Iron is a crucial element for many biological processes in companion animals, including cell growth, DNA synthesis, and electron transfer. In certain pathological conditions of companion animals, such as in tumor cells, the expression of TfR1, which mediates iron uptake, significantly increases. Therapeutic strategies targeting TfR1 may include the use of antibodies. BioVenic provides services for the development of veterinary TfR1 therapeutic antibodies, offering a one-stop solution to assist in advancing your related projects. If you have such needs, please contact us for more information.
References
- Shen, Ying, et al. "Transferrin receptor 1 in cancer: a new sight for cancer therapy." American journal of cancer research 8.6 (2018): 916.
- De Vico, Gionata, et al. "Expression of transferrin receptor‐1 (TFR‐1) in canine osteosarcomas." Veterinary Medicine and Science 6.3 (2020): 272-276.
- Rensi, Nicolò, et al. "Evaluation of TFR-1 expression in feline mammary cancer and in vitro antitumor efficacy study of doxorubicin-loaded H-ferritin nanocages." Cancers 13.6 (2021): 1248.